Chung-Han Lee, MD, PhD, discusses the types of research that are needed to push forward the development of adjuvant treatments for patients with renal cell carcinoma.
Chung-Han Lee, MD, PhD, vice president of early clinical development at Exelixis, discusses the types of research that are needed to push forward the development of adjuvant treatments for patients with renal cell carcinoma (RCC).
According to Lee, the space is in need of better predictive markers on whether or not patients have reccurrent disease, improved methods of determining which patients will respond to treatment, and the ability to predict who may develop toxicities.
TRANSCRIPTION:
0:10 | I think that there are multiple steps in which we can move this forward. One is coming up with better predictive markers on whether or not people have recurrent disease. Right now, most of the ways that we've predicted nomograms have been strictly clinical, and based on the pathology report, based off of some clinical features of the patients, and then the surgical pathology and seeing what that looks like, the size, and the grade.
0:42 | One of the things that would be interesting to move forward is now that we've developed so many prognostic markers from the genomic sort of sense, whether or not any of that can be integrated into the nomograms to help predict your risk recurrence. If we can predict with better accuracy, that will also help us better stratify patients. That's 1 component that's going to be beneficial.
1:10 | The second second part that would be beneficial is to get a better sense of predicting who might respond to treatments. If we can predict even that with better accuracy, then again, we can move the needle a bit more forward in terms of those types of treatment algorithms. The other part is our ability to predict who might develop toxicity. I think that working on all 3 of these fronts are going to be critical for defining the patients that would benefit the most.
Key Takeaways From QOL and Use of Steroids With IO-Based RCC Regimens
May 6th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Comparing Choices for IO/TKI Combinations in Advanced RCC
May 2nd 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Sustained Treatment-Free Survival in RCC Seen With Nivolumab and Ipilimumab
April 30th 2024Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Read More
Roundtable Roundup April: Renal Cell Carcinoma
April 27th 2024In separate, live virtual events, Arnab Basu, MD, MPH, and Robert J. Motzer, MD, asked participants which therapy they would choose for a patient with clear cell renal cell carcinoma (RCC) and why they would make that choice.
Read More